Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures.

about

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures.

Item

http://www.wikidata.org/entity/Q42495798

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Genomic Impact of Neoadjuvant ...... ed Diagnostic Gene Signatures.

@en

Genomic Impact of Neoadjuvant ...... ed Diagnostic Gene Signatures.

@nl

type

Item

label

Genomic Impact of Neoadjuvant ...... ed Diagnostic Gene Signatures.

@en

Genomic Impact of Neoadjuvant ...... ed Diagnostic Gene Signatures.

@nl

prefLabel

Genomic Impact of Neoadjuvant ...... ed Diagnostic Gene Signatures.

@en

Genomic Impact of Neoadjuvant ...... ed Diagnostic Gene Signatures.

@nl

P1476

Genomic Impact of Neoadjuvant ...... ed Diagnostic Gene Signatures.

@en

P2093

Erin Yoder

http://www.w3.org/2001/XMLSchema#string

James Pellicane

http://www.w3.org/2001/XMLSchema#string

Mark Gittleman

http://www.w3.org/2001/XMLSchema#string

NBRST Investigators Group

http://www.w3.org/2001/XMLSchema#string

Pat Whitworth

http://www.w3.org/2001/XMLSchema#string

Paul Baron

http://www.w3.org/2001/XMLSchema#string

Peter Beitsch

http://www.w3.org/2001/XMLSchema#string

Tina Treece

http://www.w3.org/2001/XMLSchema#string

P2860

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.

Converting a breast cancer microarray signature into a high-throughput diagnostic test.

Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

Systems biology and genomics of breast cancer.

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response.

P2888

s10434-016-5329-6

P304

3317-3323

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-016-5329-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1009335050

http://www.w3.org/2001/XMLSchema#string

P698

27384749

http://www.w3.org/2001/XMLSchema#string